Interestingly, using the same dataset (GEO accession: GSE54646; ref. 21),when comparing the expression of CHAF1B in mutant versus wild-type cohorts for the JAK2, CALR, and TET2 genes among patients with MPN (Fig. 2D–F), CHAF1B was found to be significantly higher in patients with MPN carrying a CALR mutation compared with patients carrying wild-type CALR (Fig. 2E). This evidence concerns the gene CHAF1B and myeloproliferative disorder.